This article explains what the trials found, what they did not find, and how to weigh a once-weekly product against what you use today. The results are promising on the outcomes patients care about most—fewer injections, weight, and severe lows—but they carry clear limits and open questions, including whether and when these products will reach the US market.
Why so many people delay starting insulin
Daily basal insulin is not just a medication; it is a routine that reshapes the day. A long-acting injection at roughly the same time each morning or evening must fit around work shifts, travel, family meals, and the occasional forgotten dose. When people describe the burden, three concerns dominate: injection frequency, the weight gain that is a common side effect of insulin therapy, and hypoglycemia—especially fear of a severe low that requires someone else's help. All three are recognized reasons people postpone starting or advancing insulin therapy, even when glucose control is slipping. This matters because the decision to try a once-weekly option is, at its core, a response to these specific barriers.
What a once-weekly insulin actually is
The once-weekly basal insulin at the center of this discussion is called icodec. It is not a daily insulin given less often. Its structure has been changed—amino acid modifications plus an added side chain—so that after one subcutaneous injection it releases slowly and steadily for roughly seven to eight days. That molecular design is what makes weekly dosing possible, and it explains both the convenience and the limits.
It is equally important to separate icodec from GLP-1 receptor agonists, which work in part by prompting the body to release more of its own insulin in response to meals and can support weight control. A weekly basal insulin does none of that; it simply provides background insulin to keep glucose stable between meals and overnight. The distinction sets expectations: a once-weekly basal insulin covers basal needs but will not, by itself, control the rise in blood sugar after a meal.
What the COMBINE 3a trials actually demonstrated
The European approval of the combination product rests on a set of phase 3 trials known as COMBINE, and three of those trials hit their main goals. A few terms matter before the results. HbA1c is the standard measure of average blood glucose over two to three months and is the primary yardstick in these trials. "Superior" means one treatment performed meaningfully better than a comparator. "Non-inferior" is a lower bar: it means one treatment was shown to be no worse than another within a prespecified margin—a common standard when a new option offers other advantages such as convenience.
Against that backdrop, the combination—once-weekly icodec plus the GLP-1 receptor agonist semaglutide, approved in Europe under the brand name Kyinsu (IcoSema)—proved superior to each of its single components at lowering HbA1c. It was also non-inferior to a daily basal-bolus regimen, meaning the traditional schedule of a long-acting insulin plus fast-acting insulin at meals. In plain terms, the once-weekly injection matched the daily regimen on glucose control while simplifying the schedule.
Weight and hypoglycemia were the other headline outcomes. The combination was associated with more significant weight loss compared with the weight gain typically seen with basal insulin or a daily basal-bolus regimen, and with a lower rate of clinically significant or severe hypoglycemia. To make those terms concrete: a level 2 low is a reading below 54 mg/dL, and a level 3 severe low is one where you need someone else's help to recover.
A comparison table can clarify how the once-weekly options line up against the daily approach.
| Comparison dimension | Daily basal insulin (traditional) | Once-weekly icodec | Once-weekly combination (IcoSema) |
|---|
| Injection frequency | Daily | Once weekly | Once weekly |
| Mechanism | External basal insulin covering background glucose needs | Modified insulin releasing steadily over 7–8 days | Basal insulin weekly + GLP-1 receptor agonist |
| Post-meal glucose coverage | No—requires mealtime insulin or oral medications | No—requires oral medications or rapid-acting insulin | GLP-1 component helps partly; still a weekly design |
| Weight effect (COMBINE program) | Associated with weight gain | Not reported separately in this material | More significant weight loss vs basal insulin and daily basal-bolus |
| Hypoglycemia risk (COMBINE program) | Not quantified in this material | Not reported separately in this material | Lower clinically significant or severe hypoglycemia vs comparators |
| Regulatory status | Long-established | Approved in China for type 2 diabetes; US status not confirmed | EU-approved; US status not confirmed |
The table highlights key boundaries. A weekly basal insulin covers background glucose only, so even a weekly combination is not a mealtime product in the way a fast-acting insulin is. The weight and hypoglycemia findings come from the combination product in the COMBINE program; separate numbers for icodec alone were not part of the material behind this article, and exact figures were not provided. On regulatory geography, icodec is approved in China for type 2 diabetes, the combination across the European Union plus Iceland, Norway, and Liechtenstein, and the US status of either was not confirmed here.
Where a once-weekly option could fit
The obvious strength is fewer injections. For someone who struggles to remember daily doses, travels frequently, or finds a daily injection emotionally draining, a weekly schedule removes a constant reminder of the condition. When the combination also points toward weight loss rather than weight gain and a lower rate of severe lows, it aligns with the outcomes many patients hope for.
But the limits deserve equal attention. Because a weekly basal insulin covers only basal glucose, post-meal rises still need a plan, typically oral medications or a fast-acting insulin. The combination includes a GLP-1 component, which contributes to mealtime glucose control, but it remains a once-weekly formulation rather than a substitute for paying attention to meals. It is also worth stating that there is no once-monthly insulin on the market; weekly is the current frontier of convenience.
What remains unknown
Several things are genuinely unsettled, and they should shape any decision. First, US approval. The milestones described here came from Europe and China. Whether icodec or the combination will be approved by the US Food and Drug Administration, and on what timeline, was not confirmed in the material used for this article, so anyone in the US should check domestic regulatory status rather than assume availability. Second, the results summarized here are qualitative: specific figures—how much HbA1c dropped, how many kilograms were lost, exact hypoglycemia rates—were not part of the public material behind this article; the original published trial papers are the right place to find precise numbers. Third, long-term safety and real-world adherence data will only accumulate after widespread use. Finally, a separate once-weekly dual agonist (mazdutide, targeting both GLP-1 and glucagon receptors) is being studied in China, including a trial of people switching from other GLP-1 drugs with glucose tracked by continuous monitoring. That research is registered on a Chinese clinical trial platform and says nothing about availability in the US.
Questions to bring to your next appointment
If you are in the evaluation stage—told you need to start or advance insulin and weighing your options—the most useful step is a focused conversation rather than a wait for headlines. Consider asking your doctor: Is my current HbA1c and post-meal pattern such that adding or changing medication makes sense now? How would a weekly option handle my post-meal glucose? What is my own history of low blood sugar, and would a product with a lower rate of severe lows meaningfully change my risk? How should weight concerns factor into choosing between a daily basal insulin and a weekly combination? And, practically, what is available, covered, and appropriate where I live today?
The bottom line
The COMBINE results matter because they connect three things patients repeatedly say they care about: fewer injections, better weight outcomes, and a lower risk of severe low blood sugars. But a change in diabetes treatment is not decided by headlines; it is decided by a clinician who knows your glucose patterns, weight trajectory, low-blood-sugar history, and daily life. This is a moment where regulatory progress and individual decision-making meet. The right next step is to raise the burden you actually feel—injection frequency, weight, or fear of lows—and ask whether a once-weekly option belongs in your future. A switch should be made only in discussion with the doctor who manages your care.
研究の知恵